Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Karen K Chu"'
Autor:
Stephanie Ascough, Rebecca J Ingram, Karen K Chu, Catherine J Reynolds, Julie A Musson, Mehmet Doganay, Gökhan Metan, Yusuf Ozkul, Les Baillie, Shiranee Sriskandan, Stephen J Moore, Theresa B Gallagher, Hugh Dyson, E Diane Williamson, John H Robinson, Bernard Maillere, Rosemary J Boyton, Daniel M Altmann
Publikováno v:
PLoS Pathogens, Vol 10, Iss 5, p e1004085 (2014)
Bacillus anthracis produces a binary toxin composed of protective antigen (PA) and one of two subunits, lethal factor (LF) or edema factor (EF). Most studies have concentrated on induction of toxin-specific antibodies as the correlate of protective i
Externí odkaz:
https://doaj.org/article/2a3497e4431447f1bf25d62970f3f8fb
Translating Science into Survival: Report on the Third International Cancer Immunotherapy Conference
Publikováno v:
Cancer Immunology Research. 6:10-13
On September 6 to 9, 2017, in Mainz, Germany, the Third International Cancer Immunotherapy Conference was hosted jointly by the Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the Ame
Autor:
Yusuf Ozkul, John H. Robinson, Steven A. Moore, Mehmet Doganay, Gökhan Metan, E. Diane Williamson, Karen K. Chu, Theresa B. Huwar, Hugh Dyson, Shiranee Sriskandan, Stephanie Ascough, Les Baillie, Rebecca J. Ingram, Daniel M. Altmann, Bernard Maillere, Louise U. Kim
Publikováno v:
The Journal of Immunology. 184:3814-3821
There has been a long history of defining T cell epitopes to track viral immunity and to design rational vaccines, yet few data of this type exist for bacterial infections. Bacillus anthracis, the causative agent of anthrax, is both an endemic pathog
Autor:
Brendan W. Wren, Gregory J. Bancroft, Jon Cuccui, Petra C. F. Oyston, Karen K. Chu, Richard W. Titball, Anna Easton
Publikováno v:
Infection and Immunity. 75:1186-1195
Burkholderia pseudomallei , the causative agent of melioidosis, is an important human pathogen in Southeast Asia and northern Australia for which a vaccine is unavailable. A panel of 892 double signature-tagged mutants was screened for virulence usin
Autor:
Tim Atkins, Ashraful Haque, Richard W. Titball, Anna Easton, Gregory J. Bancroft, Edouard E. Galyov, Mark P. Stevens, Karen K. Chu
Publikováno v:
The Journal of Infectious Diseases. 194:1241-1248
Burkholderia pseudomallei is the etiological agent of melioidosis, a serious human disease for which no vaccine is available. Immunization of susceptible BALB/c mice with the live attenuated mutant B. pseudomallei ilvI (referred to as "2D2") generate
Publikováno v:
Infection and Immunity. 72:6142-6147
Differences in infection kinetics and host response between Burkholderia multivorans and Burkholderia cenocepacia were demonstrated in a pulmonary infection model in BALB/c mice. B. multivorans persisted in the lung, while B. cenocepacia was cleared.
Publikováno v:
The Journal of Infectious Diseases. 190:957-966
Despite the characterization of some Burkholderia cepacia complex exopolysaccharides (EPSs), little is known about the role of EPSs in the pathogenicity of B. cepacia complex organisms. We describe 2 Burkholderia cenocepacia (genomovar III) isolates
Autor:
Helen S. Atkins, Sarah V. Harding, Bernard Maillere, Gregory J. Bancroft, Karen K. Chu, Patcharaporn Tippayawat, Nicola J. Walker, Ganjana Lertmemongkolchai, Daniel M. Altmann
Publikováno v:
European journal of immunology. 41(1)
Burkholderia pseudomallei causes melioidosis, a disease with a wide range of possible outcomes, from seroconversion and dormancy to sepsis and death. This spectrum of host-pathogen interactions poses challenging questions about the heterogeneity in i
Publikováno v:
Infection and immunity. 70(5)
Cystic fibrosis patients infected with strains from different genomovars of the Burkholderia cepacia complex can experience diverse clinical outcomes. To identify genomovar-specific determinants that might be responsible for these differences, we dev
Autor:
Der-Martirosian C; Veterans Affairs Greater Los Angeles Healthcare System/Center for the Study of Healthcare Innovation, Implementation, & Policy (CSHIIP), Los Angeles, CA, USA. claudia.der-martirosian@va.gov.; Veterans Emergency Management Evaluation Center (VEMEC), Department of Veterans Affairs, North Hills, CA, USA. claudia.der-martirosian@va.gov., Yoo CK; Veterans Affairs Greater Los Angeles Healthcare System/Center for the Study of Healthcare Innovation, Implementation, & Policy (CSHIIP), Los Angeles, CA, USA., Steers WN; Veterans Affairs Greater Los Angeles Healthcare System/Center for the Study of Healthcare Innovation, Implementation, & Policy (CSHIIP), Los Angeles, CA, USA.; Veterans Emergency Management Evaluation Center (VEMEC), Department of Veterans Affairs, North Hills, CA, USA., Hou CG; Veterans Affairs Greater Los Angeles Healthcare System/Center for the Study of Healthcare Innovation, Implementation, & Policy (CSHIIP), Los Angeles, CA, USA., Chu K; Veterans Affairs Greater Los Angeles Healthcare System/Center for the Study of Healthcare Innovation, Implementation, & Policy (CSHIIP), Los Angeles, CA, USA.; Veterans Emergency Management Evaluation Center (VEMEC), Department of Veterans Affairs, North Hills, CA, USA., Ferguson J; Center for Innovation to Implementation, Veterans Affairs Palo Alto Health Care System, Menlo Park, CA, USA., Carter M; Office of Primary Care/Patient Care Services, Veterans Health Administration, Washington, DC, USA., Heyworth L; Office of Connected Care/Telehealth Services, Veterans Health Administration, Washington, DC, USA.; Department of Medicine, University of California San Diego School of Medicine, San Diego, CA, USA., Leung LB; Veterans Affairs Greater Los Angeles Healthcare System/Center for the Study of Healthcare Innovation, Implementation, & Policy (CSHIIP), Los Angeles, CA, USA.; Department of Medicine, Division of General Internal Medicine & Health Services Research, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Publikováno v:
BMC primary care [BMC Prim Care] 2024 Sep 07; Vol. 25 (1), pp. 333. Date of Electronic Publication: 2024 Sep 07.